Harrow, Inc. 8.625% Senior Notes due 2026 (HROWL) Dividend History

Harrow, Inc. 8.625% Senior Notes due 2026 (HROWL) are unsecured debt securities issued by Harrow, Inc. The notes carry a fixed interest rate of 8.625% and are scheduled to mature in 2026. They represent a means for the company to raise capital, offering investors potentially higher yields in exchange for assuming credit risk associated with the company's financial health.

102 Woodmont Blvd, Nashville, TN, 37215
Phone: 615.733.4731

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
April 30, 2025	$0.54	04/15/2025	04/15/2025
January 31, 2025	$0.54	01/15/2025	01/15/2025
October 31, 2024	$0.54	10/15/2024	10/15/2024
July 31, 2024	$0.54	07/15/2024	07/15/2024
April 30, 2024	$0.54	04/12/2024	04/15/2024
January 31, 2024	$0.54	01/11/2024	01/15/2024
October 31, 2023	$0.54	10/12/2023	10/15/2023
July 31, 2023	$0.54	07/13/2023	07/15/2023
April 30, 2023	$0.54	04/13/2023	04/15/2023
January 31, 2023	$0.54	01/12/2023	01/15/2023
October 31, 2022	$0.54	10/13/2022	10/15/2022
July 31, 2022	$0.54	07/14/2022	07/15/2022
April 30, 2022	$0.53	04/13/2022	04/15/2022
January 31, 2022	$0.54	01/13/2022	01/15/2022
November 01, 2021	$0.54	10/14/2021	10/15/2021

Dividends Summary

Harrow, Inc. 8.625% Senior Notes due 2026 has issued 15 dividend payments over the past 4 years
The most recent dividend was paid 38 days ago, on April 30, 2025
The first recorded dividend was paid on November 1, 2021
The highest dividend payout was $0.54 per share
The average dividend over this 4 year span is $0.54 per share

Company News

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox announced that the last patient has completed the final visit in the Whistler Phase 3b clinical trial for its lead product candidate NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The results of the Denali Phase 3 trial are also expected in Q3 2025.

GlobeNewswire Inc.

Featured Companies: BLCO HROW HROWM
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'

U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.

Benzinga

Featured Companies: BKKT BON GES GETY HQY HROW HROWM IHS QQQ SGMO SPY STN
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Nicox presented additional analysis from the NCX 470 Mont Blanc Phase 3 trial, showing that more patients on NCX 470 achieved an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost. The company also provided an update on the development of NCX 470, including plans for a U.S. New Drug Application submission targeted in H1 2026.

GlobeNewswire Inc.

Featured Companies: BLCO HROW HROWM
Nicox : Présentation Scientifique et Participation aux Congrès du premier semestre 2025

Nicox, a specialty ophthalmology company, announces a poster presentation at the American Glaucoma Society Congress and participation in several key ophthalmology and finance conferences in the first half of 2025.

GlobeNewswire Inc.

Featured Companies: BLCO HROW HROWM
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025

Nicox, an international ophthalmology company, announced a presentation at the American Glaucoma Society Annual Meeting 2025 and participation in several key ophthalmology and financial conferences in the first half of 2025.

GlobeNewswire Inc.

Featured Companies: BLCO HROW HROWM

Dividend data last updated 06/06/2025 18:27:13 UTC